Pinnacle 21 Releases P21 Community 4.0 Blog Post
As of 2022年4月25日, we have released P21 Community 4.0 to general availability! Install it now from our Downloads page. P21C 4.0 is the first major release of this application…
Accelerating Oncology Drug Development with Biosimulation and Regulatory Strategy Page
Accelerating Oncology Drug Development with Biosimulation and Regulatory Strategy Trust the experts who advanced 500+ oncology projects With more than 80% of novel compounds to treat cancer coming from emerging...
PBPK Model Informs Antibody-Drug Conjugate Label for DDIs Without Clinical Trials Blog Post
Genentech was developing polatuzumab vedotin (Polivy), an anti-CD79b-vc-monomethyl auristatin E (MMAE) antibody-drug conjugate (ADC) to treat patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). MMAE is a potent...
Market Access Radar Page
マーケットアクセスレーダーは、世界中の情報源から最新の価格および償還データを取得し、マーケットアクセスに関する課題に自信を持って対応できるようサポートします。
Responsibility Page
Corporate Responsibility Certara is transforming drug development for good At Certara, we envision a future where drug development complexities are transformed into seamless, interconnected processes that bring impactful therapies to...
5 Reasons Why You Should Use Phoenix WinNonlin for PK/PD Analyses Blog Post
世界中の製薬会社は、ますます長くなる医薬品開発サイクルと高騰するコストという課題に直面しています。Each step of drug development must therefore be as accurate and efficient as…
Privacy Policy Notice for the National Health Data System (SNDS) of France Page
Privacy Policy Notice for the National Health Data System (SNDS) of France
eChalk Talk: How Oncology Drug Developers Can Prepare for FDA’s Project Optimus Blog Post
Historically, the dosing strategy for oncology drugs has focused on use of the maximum tolerated dose. This has resulted in drugs’ pharmacokinetic (PK) profiles, pharmacokinetic/pharmacodynamic (PK/PD) relationships, and clinical target…
Certara Selected by the European Medicines Agency to Provide Real World Solutions for Critical Regulatory Decisions Blog Post
Princeton, N.J., 2022年3月17日 — Certara, Inc. today announced a four-year, framework service contract with the European Medicines Agency (EMA) to advance regulatory decision-making in the human medicines domain…
